SSA
OTLK icon

Schonfeld Strategic Advisors’s Outlook Therapeutics OTLK Stock Holding History

Schonfeld Strategic Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,441,355
Closed -$3.86M – 2550
2025
Q4 		$3.86M Buy
2,441,355
+1,726,185
+241% +$2.76M 0.02% 635
2025
Q3 		$758K Sell
715,170
-649,639
-48% -$1.12M ﹤0.01% 1509
2025
Q2 		$2.18M Sell
1,364,809
-187,935
-12% -$300K 0.01% 929
2025
Q1 		$1.89M Buy
+1,552,744
New +$2.72M 0.01% 984
2024
Q4 		– Sell
-285,714
Closed -$1.53M – 2281
2024
Q3 		$1.53M Hold
285,714
– – 0.01% 1004
2024
Q2 		$2.11M Hold
285,714
– – 0.01% 883
2024
Q1 		$3.2M Buy
+285,714
New +$2.31M 0.02% 812

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Schonfeld Strategic Advisors's OTLK Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Outlook Therapeutics (OTLK) in Q1 2026, closing a stake of 2,441,355 shares — an estimated $3.86M sold.

Schonfeld Strategic Advisors first reported a position in OTLK in Q1 2024 and held it in 7 quarters. The position peaked at $3.86M in Q4 2025. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Outlook Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 2,441,355 Outlook Therapeutics shares in Q1 2026, an estimated $3.86M.
  • Schonfeld Strategic Advisors first reported a position in Outlook Therapeutics in Q1 2024 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's Outlook Therapeutics position peaked at $3.86M in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.